BiotechTube
AdjuTec Pharma

AdjuTec Pharma

Oslo, Norway· Est.
adjutecpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

AdjuTec Pharma is a private, preclinical-stage biotech founded in 2019, originating from research at the University of Oslo. The company is developing adjuvant therapies, specifically β-lactamase inhibitors, designed to break bacterial resistance and rescue last-line antibiotics like carbapenems and cephalosporins. Its lead candidate, APC148, has completed a First-In-Man study, positioning the company to tackle a critical and growing global health crisis. Backed by private funding, public grants, and a founding professor-emeritus as its largest shareholder, AdjuTec aims to bring its novel resistance-breaking combinations to market.

Infectious DiseaseAntimicrobial Resistance

Technology Platform

Synthesis of novel β-lactamase inhibitors (BLIs), targeting both serine β-lactamases (SBL) and metallo-β-lactamases (MBL), to restore efficacy of existing broad-spectrum antibiotics.

Funding History

2
Total raised:$12M
Series A$10M
Seed$2M

Opportunities

The massive and growing global burden of antimicrobial resistance (AMR), projected to cause millions of deaths annually, creates an urgent and large addressable market.
There is a specific high-need gap for effective metallo-β-lactamase (MBL) inhibitors to rescue last-line carbapenem antibiotics, where AdjuTec's early data suggests a potential best-in-class profile.
Increasing global policy and funding initiatives (e.g., CARB-X, pull incentives) aimed at stimulating antibacterial development could provide non-dilutive funding and improved market entry pathways.

Risk Factors

High clinical development risk in moving from early-phase studies to demonstrating efficacy in severe infections.
The antibacterial market presents severe commercial challenges, including low pricing, stewardship-driven limited use, and difficulty achieving profitability, which threatens financial sustainability and investor interest.
Intense competition from larger pharmaceutical companies and other biotechs developing BLI and MBL inhibitors risks technological obsolescence or market share loss.

Competitive Landscape

The β-lactamase inhibitor space is competitive, with established players like Pfizer (avibactam in Relebactam combo) and Merck (vaborbactam) focused on SBLs, and several companies developing MBL inhibitors (e.g., Venatorx's taniborbactam, Innoviva's ANT2681). AdjuTec's differentiation hinges on the novel structure and potency of its APC148 molecule, particularly against MBL-producing pathogens, as claimed by its in vitro data. Success will require outperforming these advanced competitors in clinical trials.

More companies in Small Molecule Drugs →More companies in Norway →